LEADER 01369nam  2200397Ia 450 
001 9910699222303321
005 20230902161906.0
035   $a(CKB)5470000002401686
035   $a(OCoLC)493493259
035   $a(EXLCZ)995470000002401686
100   $a20091223d2009      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aAddendum to ICH S6$b[electronic resource] $epreclinical safety evaluation of biotechnology-derived pharmaceuticals
210  1$a[Rockville, Md.?] :$c[U.S. Dept. of Health and Human Services, Food and Drug Administration],$d[2009]
215   $a1 online resource (iv, 14 pages)
300   $a"ICH harmonised tripartite guideline."
300   $a"S6(R1)."
300   $a"Current step 2 version, dated October 29, 2009."
320   $aIncludes bibliographical references (page 14).
517   $aAddendum to ICH S6 
606   $aPharmaceutical biotechnology
606   $aDrugs$xTesting
615  0$aPharmaceutical biotechnology.
615  0$aDrugs$xTesting.
712 02$aUnited States.$bFood and Drug Administration.
712 12$aInternational Conference on Harmonisation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699222303321
996   $aAddendum to ICH S6$93518709
997   $aUNINA